このエントリーをはてなブックマークに追加
ID 55446
JaLCDOI
FullText URL
71_5_453.pdf 1.91 MB
Author
Taniguchi, Akihiko Department of Allergy and Respiratory Medicine, Okayama University Hospital Kaken ID
Miyahara, Nobuaki Department of Allergy and Respiratory Medicine, Okayama University Hospital
Oda, Naohiro Department of Allergy and Respiratory Medicine, Okayama University Hospital
Morichika, Daisuke Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ichihara, Eiki Department of Allergy and Respiratory Medicine, Okayama University Hospital Kaken ID publons
Oze, Isao Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute
Tanimoto, Yasushi National Hospital Organization Minami-Okayama Medical Center
Ichikawa, Hirohisa Department of Respiratory Medicine, KKR Takamatsu Hospital
Fujii, Utako Department of Allergy and Respiratory Medicine, Okayama University Hospital
Tanimoto, Mitsune Department of Allergy and Respiratory Medicine, Okayama University Hospital Kaken ID publons researchmap
Kanehiro, Arihiko Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kiura, Katsuyuki Department of Allergy and Respiratory Medicine, Okayama University Hospital ORCID Kaken ID publons researchmap
Abstract
Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.
Keywords
chronic obstructive pulmonary disease
β-blocker
bisoprolol
exacerbation
heart failure
Amo Type
Clinical Study Protocol
Publication Title
Acta Medica Okayama
Published Date
2017-10
Volume
volume71
Issue
issue5
Publisher
Okayama University Medical School
Start Page
453
End Page
457
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
English
Copyright Holders
CopyrightⒸ 2017 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID